The Quantellect read.As of Nov 19, 2026, 4 active firms cover Immuneering Corp: 4 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $14.00 to $20.00, a moderate spread. The average target of $17.33 sits 395% above the current $3.50. The rating mix has stayed broadly stable, with Buy-side ratings easing from 6 to 4 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.40 next quarter toward $-1.64 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 active firms
Buy
Strong Buy00%
Buy4100%
Neutral00%
Sell00%
Strong Sell00%
Based on 4 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$17.33
+395.2% upside
Average target across 3 active firms as of Nov 19, 2026 vs $3.50 current
Highest Target$20.00
Average Target$17.33
Lowest Target$14.00
Detailed analyst forecasts for IMRX
Showing 1–4 of 4 named analysts shown · 4 active firms in the rating projection
As of Nov 19, 2026, 4 of 4 active firms rate IMRX a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
IMRX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.40
Range $-0.41 – $-0.38 · 3 analysts · +89% YoY
Next period, 3 analysts expect Immuneering Corp to earn $-0.40 a share (range $-0.41 – $-0.38), versus $-0.21 a year earlier. Full-year consensus is $-1.26, growing to $-1.64 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 3 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Immuneering Corp
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on IMRX.
#1
Ami Fadia
Needham · Rank #92
Buy
$18.00+414.3% to target
Overall win rate
46%
+ Follow
#2
Geulah Livshits
Chardan Capital · Rank #104
Buy
$20.00+471.4% to target
Overall win rate
43%
+ Follow
#3
Andrew Berens
Leerink Partners · Rank #162
Buy
$15.00+328.6% to target
Overall win rate
53%
+ Follow
#4
Graig Suvannavejh
Mizuho · Rank #239
Buy
$10.00+185.7% to target
Overall win rate
40%
+ Follow
#5
Andres Y. Maldonado
HC Wainwright & Co. · Rank #288
Buy
$14.00+300.0% to target
Overall win rate
39%
+ Follow
IMRX stock forecast FAQ
What is IMRX's average 12-month price target?+
The 3 active firms with a live target average $17.33 for Immuneering Corp over the next 12 months, ranging from a $20.00 high to a $14.00 low, as of Nov 19, 2026.
Is IMRX stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 4 active firms as of Nov 19, 2026, 4 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for IMRX?+
The Street-high target is $20.00 (Chardan Capital), and the Street-low is $14.00 (HC Wainwright & Co.). The average of all 3 active-firm targets is $17.33.
How many active Wall Street firms cover IMRX?+
4 active firms have a recognized rating on Immuneering Corp as of Nov 19, 2026, and 3 active firms carry a live 12-month price target.
Who is the most accurate analyst covering IMRX?+
Among analysts who currently cover IMRX, Ami Fadia of Needham has the strongest overall Quantellect track record (Rank #92). Their current call is Buy with a $18.00 target.
What is Immuneering Corp's projected EPS for next quarter?+
The consensus estimate is $-0.40 per share (range $-0.41 – $-0.38) across 3 analysts. Full-year EPS is projected at $-1.26, rising to $-1.64 the following year.
How much revenue is Immuneering Corp expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading IMRX lately?+
As of Nov 19, 2026, 4 of 4 active firms rate IMRX a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their IMRX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.